Oric Pharmaceuticals, Inc. — Director's Dealing 2021

May 14, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Oric Pharmaceuticals, Inc. (ORIC)
CIK: 0001796280
Period of Report: 2021-05-11

Reporting Person: Chacko Jacob (Director, President and CEO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-05-11	Common Stock	S	1090	$25.2198	Disposed	59310	Direct
2021-05-12	Common Stock	S	400	$25.024	Disposed	58910	Direct
2021-05-13	Common Stock	S	730	$25.0425	Disposed	58180	Direct

Footnotes

F1: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.

F2: Represents the weighted average share price of an aggregate total of 1,090 shares sold in the price range of $25.16 to $25.32 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

F3: Represents the weighted average share price of an aggregate total of 400 shares sold in the price range of $25.00 to $25.04 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

F4: Represents the weighted average share price of an aggregate total of 730 shares sold in the price range of $25.00 to $25.26 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.